Surrozen (NASDAQ:SRZN – Get Free Report) and Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.
Volatility & Risk
Surrozen has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500.
Insider & Institutional Ownership
66.6% of Surrozen shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 43.5% of Surrozen shares are owned by company insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $12.50 million | 3.14 | -$43.04 million | N/A | N/A |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -6.94 |
Tectonic Therapeutic has lower revenue, but higher earnings than Surrozen.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Surrozen and Tectonic Therapeutic, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 0 | 0 | 1 | 0 | 3.00 |
| Tectonic Therapeutic | 0 | 0 | 5 | 1 | 3.17 |
Surrozen presently has a consensus price target of $45.00, indicating a potential upside of 272.52%. Tectonic Therapeutic has a consensus price target of $72.25, indicating a potential upside of 76.65%. Given Surrozen’s higher possible upside, research analysts plainly believe Surrozen is more favorable than Tectonic Therapeutic.
Profitability
This table compares Surrozen and Tectonic Therapeutic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | N/A | -120.51% | -54.68% |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
Summary
Tectonic Therapeutic beats Surrozen on 7 of the 11 factors compared between the two stocks.
About Surrozen
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
